Avid's Rich Richieri referred your questions to us. Please note that like most public companies, Peregrine requests that all investor queries be channeled through our IR personnel. We can be reached via email at ir@biocompartners.com.
Regarding your first question, Avid has its Master/Working Cell Banks in different locations for safekeeping in case of an emergency, not batches of material. Once we make and release a batch it is typically sent directly to the relevant clinical sites.
Regarding your second question, there is no indication in any of our seven bavituximab clinical trials to date of any serious allergic reactions and at this point we do not expect to see any. While it is true that chimeric antibodies in theory have a higher risk of generating an allergic or immune response to the antibody itself, in most instances these reactions have proven to be no more than a minor issue. Our preclinical fully human PS-targeting antibodies would be expected to be less likely to generate this type of unwanted immune response, but as noted, it is really not an issue in any case.
Thank you for your support of Peregrine.
AI
Market Data 
Markets 
